Targeting rare, or underserved conditions, where the potential exists for disruptive innovation has long been a successful inside track strategy for the biopharma sector. A person doesn’t have to look any further than the niche market for a drug like Sabril® (vigabatrin), approved for human use by the FDA in 2009, as well as during […]
The Stocks To Buy Now Blog
Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.